Krisztina Zsebo, Ph.D.


Dr. Zsebo is a biopharmaceutical veteran with 34 years of experience in the Biotechnology industry, Dr. Zsebo has been involved in numerous successful ventures.   She was CEO  & President of Celladon Corporation, whereas the founding CEO for 11 years, she took the company public. She was also an Entrepreneur in Residence at Enterprise Partners Venture Capital. Prior to joining Enterprise, she was CEO  & President of Remedyne Corporation. Before coming to Remedyne she was Executive Vice President of Connetics Corporation.  Dr. Zsebo also headed the Biopharmaceutical and Implant Division of ALZA Corporation, where she was responsible for the division which developed and filed the NDA for Viadur®, an implantable drug/device for prostate cancer patients. At Cell Genesys, where she was Executive Vice President of Research and Product Development, she was responsible for filing their first IND for a gene therapy product for AIDS. She also managed Cell Genesys’ Xenotech division, which was spun off to become Abgenix, one of the most successful biotech companies.  Earlier in her career, Kris spent eight years at Amgen in research and product development where she worked on the discovery of NEUPOGEN®, as well as Stem Cell Factor, and various aspects of EPOGEN® development. Dr. Zsebo received a B.S. in Biochemistry from the University of Maryland, a M.S. in Biochemistry and Biophysics from Oregon State University and a PhD in Comparative Biochemistry and Molecular Biology from the University of California, Berkeley.

Michael S. Egan


Mr. Egan has spent over 35 years working in the travel industry. He started at Alamo Rent A Car, Inc. in 1973, became an owner in 1979, and became chairman and majority owner from 1986 to 1996 when he sold the company to AutoNation. In 2000, AutoNation spun off the car rental division and he was named chairman and served in that position until 2003. Since 1996, Mr.Egan has served as the controlling investor of Dancing Bear Investments, Inc., a privately held investment company. Prior to his many business successes, Mr. Egan held various administration positions at Yale University and taught at the University of Massachusetts at Amherst. He is a graduate of the Cornell University School of Hotel Administration . Throughout his career, he has been presented with many honors and awards, including the prestigious Horatio Alger Distinguished American Award in 1997.

Elena Dneprovskaia, Ph.D.


Dr. Dneprovskaia joined Actavalon in 2015 to lead the company’s drug discovery and development programs. She has over 15 years of experience in medicinal chemistry and chemical biology with a strong focus on oncology. Prior to joining Actavalon in 2015, Elena was a Co-Founder and Chief Scientific Officer of Ailuros Biosciences, LLC, a privately held drug discovery company. Previously, she held positions of increasing responsibility in Research and Development at Trega Biosciences, Inc., Lion Bioscience, GmbH., and TargeGen, Inc., where she worked on the development of novel investigational drugs for oncology, ocular, metabolic and cardiovascular diseases and obesity. Dr. Dneprovskaia graduated from Higher Chemical College of the Russian Academy of Sciences in Moscow, Russia and received her Ph.D. in organic chemistry from Iowa State University.